Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas

Brandon G. Smaglo, Anteneh Tesfaye, Thorvardur R. Halfdanarson, Joshua E. Meyer, Jue Wang, Zoran Gatalica, Sandeep Reddy, David Arguello, Patrick M. Boland

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Anal squamous cell carcinoma (ASCC) is a rare, HPV-associated malignancy typically diagnosed in early stages and definitively treated with chemoradiation. In situations where patients exhibit metastatic or recurrent disease, treatment options are severely limited. In this study, molecular alterations were identified that could be used to aid in therapeutic decisions for patients with metastatic or recurrent anal squamous cell carcinoma. Specimens from patients with this cancer were tested via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting of gene sequencing, protein expression by immunohistochemistry, and gene amplification with in situ hybridization. Utilizing these techniques, novel treatment strategies that could be explored were identified, including potential benefit with anti-EGFR therapies, immune checkpoint inhibitors, topoisomerase inhibitors, and taxanes. The frequency of overexpression of proteins that mark resistance to chemotherapeutic drugs, such as MRP1 (chemotherapy efflux pump), ERCC1 (resistance to platinum-based chemotherapy), and thymidylate synthase (resistance to fluoropyrimidines) were also identified, suggesting a lack of benefit. This multiplatform strategy could be explored for its potential to generate a personalized treatment selection for patients with advanced ASCC, provide a guide for future therapeutic development for this cancer, and be extended to other rare cancer types as well.

Original languageEnglish (US)
Pages (from-to)43594-43604
Number of pages11
JournalOncotarget
Volume6
Issue number41
DOIs
StatePublished - Jan 1 2015

Fingerprint

Squamous Cell Carcinoma
Biomarkers
Neoplasms
Therapeutics
Topoisomerase Inhibitors
Drug Therapy
Taxoids
Thymidylate Synthase
Biological Science Disciplines
Gene Amplification
Platinum
Patient Selection
In Situ Hybridization
Proteins
Immunohistochemistry
Pharmaceutical Preparations

Keywords

  • Anal squamous cell carcinoma
  • Biomarker analysis
  • Tumor profile

ASJC Scopus subject areas

  • Oncology

Cite this

Smaglo, B. G., Tesfaye, A., Halfdanarson, T. R., Meyer, J. E., Wang, J., Gatalica, Z., ... Boland, P. M. (2015). Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget, 6(41), 43594-43604. https://doi.org/10.18632/oncotarget.6202

Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. / Smaglo, Brandon G.; Tesfaye, Anteneh; Halfdanarson, Thorvardur R.; Meyer, Joshua E.; Wang, Jue; Gatalica, Zoran; Reddy, Sandeep; Arguello, David; Boland, Patrick M.

In: Oncotarget, Vol. 6, No. 41, 01.01.2015, p. 43594-43604.

Research output: Contribution to journalArticle

Smaglo, BG, Tesfaye, A, Halfdanarson, TR, Meyer, JE, Wang, J, Gatalica, Z, Reddy, S, Arguello, D & Boland, PM 2015, 'Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas', Oncotarget, vol. 6, no. 41, pp. 43594-43604. https://doi.org/10.18632/oncotarget.6202
Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015 Jan 1;6(41):43594-43604. https://doi.org/10.18632/oncotarget.6202
Smaglo, Brandon G. ; Tesfaye, Anteneh ; Halfdanarson, Thorvardur R. ; Meyer, Joshua E. ; Wang, Jue ; Gatalica, Zoran ; Reddy, Sandeep ; Arguello, David ; Boland, Patrick M. / Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. In: Oncotarget. 2015 ; Vol. 6, No. 41. pp. 43594-43604.
@article{c1a35cc8267845169715ee317ebd753d,
title = "Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas",
abstract = "Anal squamous cell carcinoma (ASCC) is a rare, HPV-associated malignancy typically diagnosed in early stages and definitively treated with chemoradiation. In situations where patients exhibit metastatic or recurrent disease, treatment options are severely limited. In this study, molecular alterations were identified that could be used to aid in therapeutic decisions for patients with metastatic or recurrent anal squamous cell carcinoma. Specimens from patients with this cancer were tested via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting of gene sequencing, protein expression by immunohistochemistry, and gene amplification with in situ hybridization. Utilizing these techniques, novel treatment strategies that could be explored were identified, including potential benefit with anti-EGFR therapies, immune checkpoint inhibitors, topoisomerase inhibitors, and taxanes. The frequency of overexpression of proteins that mark resistance to chemotherapeutic drugs, such as MRP1 (chemotherapy efflux pump), ERCC1 (resistance to platinum-based chemotherapy), and thymidylate synthase (resistance to fluoropyrimidines) were also identified, suggesting a lack of benefit. This multiplatform strategy could be explored for its potential to generate a personalized treatment selection for patients with advanced ASCC, provide a guide for future therapeutic development for this cancer, and be extended to other rare cancer types as well.",
keywords = "Anal squamous cell carcinoma, Biomarker analysis, Tumor profile",
author = "Smaglo, {Brandon G.} and Anteneh Tesfaye and Halfdanarson, {Thorvardur R.} and Meyer, {Joshua E.} and Jue Wang and Zoran Gatalica and Sandeep Reddy and David Arguello and Boland, {Patrick M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.6202",
language = "English (US)",
volume = "6",
pages = "43594--43604",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "41",

}

TY - JOUR

T1 - Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas

AU - Smaglo, Brandon G.

AU - Tesfaye, Anteneh

AU - Halfdanarson, Thorvardur R.

AU - Meyer, Joshua E.

AU - Wang, Jue

AU - Gatalica, Zoran

AU - Reddy, Sandeep

AU - Arguello, David

AU - Boland, Patrick M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Anal squamous cell carcinoma (ASCC) is a rare, HPV-associated malignancy typically diagnosed in early stages and definitively treated with chemoradiation. In situations where patients exhibit metastatic or recurrent disease, treatment options are severely limited. In this study, molecular alterations were identified that could be used to aid in therapeutic decisions for patients with metastatic or recurrent anal squamous cell carcinoma. Specimens from patients with this cancer were tested via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting of gene sequencing, protein expression by immunohistochemistry, and gene amplification with in situ hybridization. Utilizing these techniques, novel treatment strategies that could be explored were identified, including potential benefit with anti-EGFR therapies, immune checkpoint inhibitors, topoisomerase inhibitors, and taxanes. The frequency of overexpression of proteins that mark resistance to chemotherapeutic drugs, such as MRP1 (chemotherapy efflux pump), ERCC1 (resistance to platinum-based chemotherapy), and thymidylate synthase (resistance to fluoropyrimidines) were also identified, suggesting a lack of benefit. This multiplatform strategy could be explored for its potential to generate a personalized treatment selection for patients with advanced ASCC, provide a guide for future therapeutic development for this cancer, and be extended to other rare cancer types as well.

AB - Anal squamous cell carcinoma (ASCC) is a rare, HPV-associated malignancy typically diagnosed in early stages and definitively treated with chemoradiation. In situations where patients exhibit metastatic or recurrent disease, treatment options are severely limited. In this study, molecular alterations were identified that could be used to aid in therapeutic decisions for patients with metastatic or recurrent anal squamous cell carcinoma. Specimens from patients with this cancer were tested via a multiplatform profiling service (Caris Life Sciences, Phoenix, AZ) consisting of gene sequencing, protein expression by immunohistochemistry, and gene amplification with in situ hybridization. Utilizing these techniques, novel treatment strategies that could be explored were identified, including potential benefit with anti-EGFR therapies, immune checkpoint inhibitors, topoisomerase inhibitors, and taxanes. The frequency of overexpression of proteins that mark resistance to chemotherapeutic drugs, such as MRP1 (chemotherapy efflux pump), ERCC1 (resistance to platinum-based chemotherapy), and thymidylate synthase (resistance to fluoropyrimidines) were also identified, suggesting a lack of benefit. This multiplatform strategy could be explored for its potential to generate a personalized treatment selection for patients with advanced ASCC, provide a guide for future therapeutic development for this cancer, and be extended to other rare cancer types as well.

KW - Anal squamous cell carcinoma

KW - Biomarker analysis

KW - Tumor profile

UR - http://www.scopus.com/inward/record.url?scp=84952948280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952948280&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6202

DO - 10.18632/oncotarget.6202

M3 - Article

C2 - 26498363

AN - SCOPUS:84952948280

VL - 6

SP - 43594

EP - 43604

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -